What is HC Wainwright’s Forecast for MIST FY2028 Earnings?

Posted by Francis Steltz on Aug 13th, 2026

Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Free Report) – Stock analysts at HC Wainwright lowered their FY2028 earnings per share (EPS) estimates for Milestone Pharmaceuticals in a research note issued to investors on Wednesday, August 12th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of $0.38 for the year, down from their prior estimate of $0.43. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.83) per share.

MIST has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research report on Tuesday, July 14th. Wells Fargo & Company reduced their target price on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating for the company in a research report on Thursday, May 14th. Wall Street Zen lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Sunday, May 17th. Finally, Zacks Research upgraded shares of Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Milestone Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $7.25.

Check Out Our Latest Report on Milestone Pharmaceuticals

Milestone Pharmaceuticals Trading Down 11.4%

NASDAQ MIST opened at $1.12 on Thursday. The business’s fifty day moving average is $1.24 and its 200-day moving average is $1.53. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.18 and a quick ratio of 9.09. The stock has a market capitalization of $140.06 million, a price-to-earnings ratio of -1.65 and a beta of 0.98. Milestone Pharmaceuticals has a one year low of $1.00 and a one year high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The business had revenue of $0.56 million during the quarter, compared to analyst estimates of $0.82 million.

Institutional Trading of Milestone Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of MIST. Orbimed Advisors LLC bought a new position in Milestone Pharmaceuticals in the 3rd quarter worth approximately $6,444,000. Marshall Wace LLP grew its stake in Milestone Pharmaceuticals by 289.8% in the 4th quarter. Marshall Wace LLP now owns 1,656,821 shares of the company’s stock valued at $3,347,000 after buying an additional 1,231,793 shares in the last quarter. Pathstone Holdings LLC bought a new stake in Milestone Pharmaceuticals during the 3rd quarter valued at $2,000,000. Two Sigma Investments LP bought a new stake in Milestone Pharmaceuticals during the 3rd quarter valued at $1,333,000. Finally, Millennium Management LLC purchased a new stake in shares of Milestone Pharmaceuticals during the third quarter worth $803,000. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals News Summary

Here are the key news stories impacting Milestone Pharmaceuticals this week:

Positive Sentiment: CARDAMYST coverage expanded to more than 50% of commercially insured U.S. lives, up substantially from approximately 25% earlier in the year. The company also reported more than 800 prescribers and 1,500 prescriptions through June 30, suggesting increasing market access. Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Positive Sentiment: The Phase 3 ReVeRA-301 trial of etripamil for atrial fibrillation with rapid ventricular rate is open with clinical sites activated, creating a potential second indication and larger commercial opportunity. Milestone Pharmaceuticals Reports Q2 2026 Results
Positive Sentiment: Milestone ended the quarter with $170.6 million in cash, cash equivalents and short-term investments, which management expects will fund operations into the second half of 2027.
Neutral Sentiment: Regulatory reviews for PSVT applications in Europe and China remain ongoing, with a potential European decision expected in the first half of 2027. The earnings call provided additional discussion of the commercial launch and development pipeline. Milestone Pharmaceuticals Q2 2026 Earnings Call Transcript
Negative Sentiment: Second-quarter EPS was a loss of $0.21, missing the consensus loss estimate of $0.20, while revenue of $0.56 million fell short of the $0.82 million forecast. Milestone Pharmaceuticals Reports Q2 Loss, Lags Revenue Estimates
Negative Sentiment: Net loss widened to $28.6 million from $13.0 million a year earlier, driven largely by selling, general and administrative expenses that more than doubled to $22.6 million as CARDAMYST commercialization ramped up. Product revenue remained modest at $0.6 million, raising concerns about adoption and the pace of revenue growth. Milestone Pharmaceuticals Shares Tumble After Q2 Earnings Miss

Milestone Pharmaceuticals Company Profile

(Get Free Report)

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.